BACKGROUND: Tumor-derived cell lines are widely used to study the mechanisms involved in thyroid carcinogenesis but recent studies have reported redundancy among thyroid cancer cell lines and identification of some "thyroid cell lines" that are likely not of thyroid origin. SUMMARY: In this review, we have summarized the uses, the limitations, and the existing problems associated with the available follicular cell-derived thyroid cancer cell lines. There are some limitations to the use of cell lines as a model to "mimic" in vivo tumors. Based on the gene expression profiles of thyroid cell lines originating from tumors of different types it has become apparent that some of the cell lines are closely related to each other and to those of undifferentiated carcinomas. Further, many cell lines have lost the expression of thyroid-specific genes and have altered karyotypes, while they exhibit activation of several oncogenes (BRAF, v-raf murine sarcoma viral oncogene homolog B1; RAS, rat sarcoma; and RET/PTC, rearranged in transformation/papillary thyroid carcinoma) and inactivation of tumor suppressor gene (TP53) which is known to be important for thyroid tumorigenesis. CONCLUSIONS: A careful selection of thyroid cancer cell lines that reflect the major characteristics of a particular type of thyroid cancer being investigated could be used as a good model system to analyze the signaling pathways that may be important in thyroid carcinogenesis. Further, the review of literature also suggests that some of the limitations can be overcome by using multiple cell lines derived from the same type of tumor.
BACKGROUND:Tumor-derived cell lines are widely used to study the mechanisms involved in thyroid carcinogenesis but recent studies have reported redundancy among thyroid cancer cell lines and identification of some "thyroid cell lines" that are likely not of thyroid origin. SUMMARY: In this review, we have summarized the uses, the limitations, and the existing problems associated with the available follicular cell-derived thyroid cancer cell lines. There are some limitations to the use of cell lines as a model to "mimic" in vivo tumors. Based on the gene expression profiles of thyroid cell lines originating from tumors of different types it has become apparent that some of the cell lines are closely related to each other and to those of undifferentiated carcinomas. Further, many cell lines have lost the expression of thyroid-specific genes and have altered karyotypes, while they exhibit activation of several oncogenes (BRAF, v-raf murine sarcoma viral oncogene homolog B1; RAS, ratsarcoma; and RET/PTC, rearranged in transformation/papillary thyroid carcinoma) and inactivation of tumor suppressor gene (TP53) which is known to be important for thyroid tumorigenesis. CONCLUSIONS: A careful selection of thyroid cancer cell lines that reflect the major characteristics of a particular type of thyroid cancer being investigated could be used as a good model system to analyze the signaling pathways that may be important in thyroid carcinogenesis. Further, the review of literature also suggests that some of the limitations can be overcome by using multiple cell lines derived from the same type of tumor.
Authors: J R Masters; J A Thomson; B Daly-Burns; Y A Reid; W G Dirks; P Packer; L H Toji; T Ohno; H Tanabe; C F Arlett; L R Kelland; M Harrison; A Virmani; T H Ward; K L Ayres; P G Debenham Journal: Proc Natl Acad Sci U S A Date: 2001-06-19 Impact factor: 11.205
Authors: M O Hoque; E Rosenbaum; W H Westra; M Xing; P Ladenson; M A Zeiger; D Sidransky; C B Umbricht Journal: J Clin Endocrinol Metab Date: 2005-04-19 Impact factor: 5.958
Authors: Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen Journal: J Clin Endocrinol Metab Date: 2008-08-19 Impact factor: 5.958
Authors: Yanqiang Wang; Huiling He; Wei Li; John Phay; Rulong Shen; Lianbo Yu; Baris Hancioglu; Albert de la Chapelle Journal: Proc Natl Acad Sci U S A Date: 2017-01-03 Impact factor: 11.205
Authors: Kristen Hopperstad; Theresa Truschel; Tom Wahlicht; Wendy Stewart; Andrew Eicher; Tobias May; Chad Deisenroth Journal: Appl In Vitro Toxicol Date: 2021-06-16
Authors: Yanqiang Wang; Wei Li; John E Phay; Rulong Shen; Natalia S Pellegata; Motoyasu Saji; Matthew D Ringel; Albert de la Chapelle; Huiling He Journal: Thyroid Date: 2016-07-06 Impact factor: 6.568
Authors: Irene M Min; Enda Shevlin; Yogindra Vedvyas; Marjan Zaman; Brian Wyrwas; Theresa Scognamiglio; Maureen D Moore; Weibin Wang; Susan Park; Spencer Park; Suraj Panjwani; Katherine D Gray; Andrew B Tassler; Rasa Zarnegar; Thomas J Fahey; Moonsoo M Jin Journal: Clin Cancer Res Date: 2017-10-12 Impact factor: 12.531